Lanreotide

Phase 3

Ipsen S.A. (IPN.PA)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

IPN.PAPhase 2$13.2B

Lanreotide Phase 2 Est. Readout

Lanreotide• Gastroenteropancreatic Neuroendocrine Tumors10

Mar 2027~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Gastroenteropancreatic Neuroendocrine Tumors

View Full Landscape

Drug Information

Target Indication

Gastroenteropancreatic Neuroendocrine Tumors

Clinical Trial

NCT03043664

Last updated: 8/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IPN.PA

Ipsen S.A.

Pharmaceutical Preparations•Europe•Euronext Paris

Related Pipeline

IPN10200Phase 3

Moderate to Severe Glabellar Lines

Lanreotide autogelPhase 3

Gastroenteropancreatic Neuroendocrine Tumor

CorabotasePhase 3

Cervical Dystonia

lanreotide (Autogel formulation)Phase 3

Diarrhea

ElafibranorPhase 3

Primary Biliary Cholangitis (PBC)

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts